Admaius Capital Partners has formed a strategic partnership with Triquera B.V., majority owner of Cairo-based biotech manufacturer Minapharm Pharmaceuticals. The investment marks a significant step in advancing biopharmaceutical innovation and manufacturing capacity in the region.
About the Partners
Admaius Capital Partners is based in Mauritius and targets high-growth opportunities across the African continent. Its portfolio spans sectors such as healthcare, technology, and consumer industries, with a focus on long-term value creation and impact.
Triquera B.V. is a Dutch holding company with full ownership of Minapharm and its German subsidiary, ProBioGen. Minapharm operates one of the most advanced biopharma platforms in the Middle East and Africa, producing complex biologics including monoclonal antibodies, viral vectors, and cell and gene therapies. Its operations combine local manufacturing in Egypt with research and development conducted in Berlin.
What the Partnership Aims to Do
While the investment by Admaius is a minority stake, it is nevertheless expected to support Triquera and Minapharm in expanding their production footprint and accelerating their ambitions to become a regional biotechnology leader.
The deal will enable:
- Increased capacity for the development and manufacturing of advanced biologics.
- Expansion into global contract development and manufacturing (CDMO) services.
- Strengthening of Minapharm’s licensing and commercialisation pipeline.
- Greater access to affordable therapies in emerging markets.
- The companies aim to harness local infrastructure and global regulatory standards to deliver complex therapies at scale.
A Strategic Step for Regional Biotech
The partnership reflects a broader trend of building self-reliant, innovation-led health systems in Africa and the Middle East. With many countries still reliant on imported therapies, particularly for complex diseases, this deal is positioned to increase regional access to high-quality biologics while boosting local expertise.
Minapharm has licensed and produced therapies with global partners, approved by top regulators like the FDA and EMA. The support from Admaius gives the company additional capacity to expand this model across the region.
Future Impact
The partnership between Admaius Capital Partners and Triquera signals a growing interest in localising the production of advanced medicines in Africa and the Middle East. It positions Minapharm to scale its technical capacity and commercial reach, while supporting regional goals of health sovereignty and innovation-led growth.
In turn, Admaius strengthens its exposure to a high-potential sector, thereby positioning itself for long-term impact across both economic and healthcare outcomes.
